Aptorum Group Limited (APM)
| Market Cap | 13.07M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -4.27M |
| Shares Out | 7.14M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 160,936 |
| Open | 1.990 |
| Previous Close | 1.960 |
| Day's Range | 1.791 - 1.990 |
| 52-Week Range | 0.460 - 7.490 |
| Beta | -0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Apr 30, 2025 |
About APM
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pse... [Read more]
Financial Performance
Financial StatementsNews
Aptorum Group and DiamiR Biosciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedi...
Why Is Nano-Cap Aptorum Stock Rallying On Thursday?
Aptorum shares trade higher on 168.16 million volume vs 3.25 million average. DiamiR gains CLEP approval for APOE Genotyping test in New York.
DiamiR Biosciences and Aptorum Group Announce New York State Approval for DiamiR's APOE Genotyping Test
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and oth...
Andean Precious Metals Corp. (ANPMF) Q2 2025 Earnings Call Transcript
Andean Precious Metals Corp. (OTCQX:ANPMF) Q2 2025 Earnings Conference Call August 13, 2025 9:00 AM ET Company Participants Alberto Morales - Founder, CEO & Executive Chairman Amanda Mallough - Corpor...
Aptorum Group Limited Regains Compliance with NASDAQ's Minimum Bid Price Requirement
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet ...
Aptorum Group Limited and DiamiR Biosciences Enter into Definitive Merger Agreement
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet ...
Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC...
Synology Launches ActiveProtect: Simplifying Enterprise Data Protection with Unmatched Security, and Scalability
BELLEVUE, Wash.--(BUSINESS WIRE)--Synology launches the ActiveProtect series a unified enterprise backup solution set to disrupt the current data backup market.
Aptorum Group Limited Announces Pricing of $3.0 Million Registered Direct Offering
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs ...
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, auto...
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, auto...
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced t...
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncol...
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology,...
Aptorum Group Receives Nasdaq Approval to Transfer Listing to Nasdaq Capital Markets
NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announced that it has received an approval letter from the Na...
Aptorum Group Updates on a Phase 1b/2a Clinical Trial for Repurposed Small Molecule Drug SACT-1 for Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the t...
Aptorum Group Limited Announces Voluntary Delisting from Euronext Paris
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (the “Company”) (NASDAQ:APM, Euronext Paris:APM) announced today that following a comprehensive review of the trading...
Aptorum Group Receives Nasdaq Notification of Minimum Stockholders' Equity Deficiency
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicat...
Aptorum Therapeutics Limited Enters Into Letter of Intent and Term Sheet with Universal Sequencing Technology Corporation to Merge with Aptorum Group's Subsidiary Paths Innovations Limited
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that its wholly owned subsidiary A...
Aptorum Group Limited Reports 2022 Fiscal Year End Financial Results and Provides Business Update
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to...
Aptorum Group Enters into Letter of Intent and Term Sheet To Acquire U Group
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Company”), today announced that it entered into a non-binding...
Aptorum Group Limited and ASP Isotopes Inc. Interviews to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / March 17, 2023 / RedChip Companies will air new interviews with Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) and ASP Isotopes Inc. (Nasdaq:ASPI) on The RedChip Mon...
Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...
Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announ...